NDAINTRAVENOUSINJECTABLE
Lifecycle
Pre-Launch
Clinical Trials
20
Data completeness
4/8 — Partial
APREPITANT (aprepitant) by R-Pharm US is high-affinity antagonist of human substance p/neurokinin 1 (nk 1 ) receptors. Approved for postoperative nausea and vomiting, chemotherapy-induced nausea and vomiting, nausea and 16 more indications.
Drug data last refreshed 2w ago
Mechanism of Action
high-affinity antagonist of human substance P/neurokinin 1 (NK 1 ) receptors. Aprepitant has little or no affinity for serotonin (5-HT 3 ), dopamine, and corticosteroid receptors, the targets of existing therapies for chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea and…
Worked on APREPITANT at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.